Skip to main content Skip to main content
Go to homepage
Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

Study to determine the safety/tolerability of SNDX-5613

Study to determine the safety and tolerability of SNDX-5613 in patients with relapsed/refractory leukemia

Description:

For complete information, please visit the study at clinicaltrials.gov.

Interested in participating?
We are currently recruiting
Study Sponsor:

Syndax Pharmaceuticals; Children's Oncology Group

Full IRB Study Title:
AALL2121-A Phase 2 study of SNDX-5613 in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia
IRB Study ID:
2024-010
If you are interested in this study or have questions about your child's eligibility, please contact:

Kelly Culp: 330-543-0108

Lead Investigator
Erin Wright, MD

Director, Neuro-Oncology; Director, Shannon E. Wilkes Targeted Therapy Program; Co-Director, Neurofibromatosis Clinic; Pediatric Neuro-Oncologist
Pediatric Brain Tumor ProgramShowers Family Center for Childhood Cancer and Blood DisordersNeurofibromatosis (NF) Clinic

Starting Locations:
Career Opportunities
Legal:
Mobile App:

Akron Children's Anywhere:

About Akron Children's

While we are ranked among the best children's hospitals in the country, it's our compassionate approach to treatment that makes us truly exceptional. Through a combination of revolutionary treatments and extraordinary patient experiences, our care does more than heal. It brings the entire family together for emotional support and understanding across multiple locations to reach you in the community where you live. Learn more...

Akron Children's
One Perkins Square, Akron, Ohio 44308-1062
330-543-1000 • webmaster@akronchildrens.org
An Equal Opportunity Employer
Copyright © 2020, Akron Children's. All Rights Reserved.
  • Magnet Recongnition
  • Newsweek: World's Best Hospitals - 2023
  • Newsweek: World's Best Hospitals - Pediatrics 2023

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.